@the_news_21
Major pharmaceutical company Cipla has announced the launch of its RT-PCR test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems.
“This launch will help address the current testing services and capacity issues while reaffirming the company’s ongoing expansion in the diagnostic space,” Cipla said in a regulatory filing.
Cipla will launch the ViraGen test kit in the country in partnership with Ubio Biotechnology Systems, the company stated.
ViraGen is a real-time detection kit approved by the ICMR (Indian Council of Medical Research). It is based on multiplex PCR technology and helps to identify and detect SARS CoV-2 N Gene and ORF Lab Gene with the sensitivity of 98.6 percent and the specificity of 98.8 percent as compared to a standard ICMR test, according to biospectrumindia.com.
